Bio-Rad Introduces Bio-Plex Pro Human IgG SARS-CoV-2 Serology Assays
The Qualitative Multiplex Immunoassay Panel Provides Precise, Specific, and Sensitive Detection of IgG Antibodies Against Four SARS-CoV-2 Antigens
HERCULES, Calif. —Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel, for research use only (RUO).
The qualitative multiplex immunoassay kit quickly and efficiently detects IgG antibodies against four SARS-CoV-2 antigens, enabling vaccine developers to determine therapeutic efficacy from development through all clinical phases. In addition, the kit enables public health researchers to perform seroprevalence studies. This could help to identify the number of persons in a population who have been exposed to SARS-CoV-2 based on serology specimens, capturing individuals who have not received a COVID-19 diagnosis due to experiencing only mild symptoms or being asymptomatic.
"Detecting levels of antibodies against SARS-CoV-2 provides useful information about natural exposure rates in a population or about vaccine immunogenicity," said Candice Cox, Bio-Rad Immunoassays Marketing Manager, Life Science Group. "We are pleased to be able to offer this new immunoassay kit to researchers working in vaccine development and related fields."
About the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel
The Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel is a ready-to-use 96-well kit containing premixed magnetic capture beads, an IgG-specific detection antibody, positive and negative controls, and buffers that produce results for four anti–SARS-CoV-2 antibodies using only 5 microliters of sample. The offering includes singleplex assay reagents, enabling measurement of specific viral antigens of interest, and improves laboratory efficiency by generating key actionable data in a single experiment. The kit is compatible with RUO Bio-Rad platforms, including the Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, as well as all other RUO xMAP platforms.
- Helps researchers simultaneously profile antibodies against four SARS-CoV-2 viral antigens (nucleocapsid protein (N) and the receptor binding domain (RBD), spike 1 subunit (S1), and spike 2 subunit (S2) of the spike protein) in under 3 hours
- Confirms detectable IgG levels based on median fluorescence intensity (MFI) cutoff values
- Enables comparison of MFI values of samples to help researchers and vaccine developers understand both the strength of response and antibody levels at different time points after SARS-CoV-2 infection or vaccination
The coupled beads can be used to measure antibodies in any species, making the assay useful for both preclinical and clinical trials. For more information about the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel and other Bio-Plex instruments, assays, and software, please visit bio-rad.com/Bio-PlexCOVIDAbs.
BIO-RAD and BIO-PLEX are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. The Bio-Plex Suspension Array System includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation. LUMINEX and XMAP are trademarks of the Luminex Corporation. All trademarks used herein are the property of their respective owner.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Nico Tuason, Sr. Marketing Manager
Dr. Michelle Ricketts
+44 (0)778 9053 885